SELLAS Life Sciences (SLS) has announced that the European Commission has granted Orphan Drug Designation (ODD) for SLS009, a highly selective CDK9 inhibitor, for treating acute myeloid leukemia (AML). The company confirmed that it is on schedule to release additional data regarding SLS009 in the third quarter of this year.
"This designation, combined with the recently disclosed strong preliminary Phase 2 data and previous FDA ODD designation, underscores our ongoing progress and dedication to developing SLS009 as a potential treatment for AML," stated Angelos Stergiou, CEO of SELLAS.
